Marken continues their expansion of services in India, by augmenting their existing Mumbai facility with four additional branches to support the growing demand in clinical trial logistics within India. The expansion in New Delhi, Hydrabad, Pune and Bangalore will support the growing need for temperature controlled logistics of sensitive drugs and cold chain specimens. As part of their expansion in India, Marken recently ran a special client Awareness workshop on the air transport of infectious substances.
Marken is implementing their stated plan to build the most advanced, fit for purpose clinical Supply chain network to serve the pharmaceutical community. The new India offices build on Marken’s current clinical trial support services and enable the company to grow from its current industry-leading life sciences logistics platform. Marken is expanding their reach throughout India to support their clients rapidly increasing demand for supply chain management services of Active Pharmaceutical Ingredients (API), Investigational Medical Products (IMPs) and Clinical Trial Specimens.
“The expansion of our operations in India enables Marken to better support our clients’ need for regional expertise and temperature controlled supply chain services.” said Wes Wheeler, Marken’s Chief Executive Officer. “We have seen steady growth and demand of our specimen logistics, drug distribution and API supply chain services in India.”
Marken is currently developing a new purpose-built GMP compliant depot in Bangalore due to be complete by the end of 2012. The Bangalore Depot will join Marken’s already operational Argentina, Mexico and Singapore depots offering the full range of temperature controlled storage capabilities including: controlled ambient, refrigerated and frozen as Pharmaceuticals and Medical devices. Each of Marken’s depots provides drug and equipment distribution solutions including: Pick & Pack, relabeling services, reverse logistics, reconciliation and certified destruction. Additionally, the network manages specimen kit distribution, interim specimen storage and management.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.